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BACKGROUND: Approximately one-half of Brazilian patients with hereditary hemochromatosis (HH) are neither homozygous for 
the C282Y mutation nor compound heterozygous for the H63D and C282Y mutations that are associated with HH in Caucasians. 
Other mutations have been described in the HFE gene as well as in genes involved in iron metabolism, such as transferrin receptor 
2 (TfR2) and ferroportin 1 (SCL40A1).
AIMS: To evaluate the role of HFE, TfR2 and SCL40A1 mutations in Brazilian subjects with HH.  
PATIENTS AND METHODS: Nineteen male subjects (median age 42 [range: 20-72] years) with HH were evaluated using the 
Haemochromatosis StripAssay A®.  This assay is capable of detecting twelve HFE mutations, which are V53M, V59M, H63D, 
H63H, S65C, Q127H, P160delC, E168Q, E168X, W169X, C282Y and Q283, four TfR2 mutations, which are E60X, M172K, 
Y250X, AVAQ594-597del, and two SCL40A1 mutations, which are N144H and V162del. 
RESULTS:  In our cohort, nine (47%) patients were homozygous for the C282Y mutation, two (11%) were heterozygous for the 
H63D mutation, and one each (5%) was either heterozygous for C282Y or compound heterozygous for C282Y and H63D. No 
other mutations in the HFE, TfR2 or SCL40A1 genes were observed in the studied patients. 
CONCLUSIONS: One-third of Brazilian subjects with the classical phenotype of HH do not carry HFE or other mutations that 
are currently associated with the disease in Caucasians.  This observation suggests a role for other yet unknown mutations in the 
aforementioned genes or in other genes involved in iron homeostasis in the pathogenesis of HH in Brazil.
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INTRODUCTION
Hereditary hemochromatosis (HH) is a recessive 
inherited disorder of iron metabolism that is characterized 
by systemic iron overload as a result of enhanced intestinal 
absorption.1,2 The disease usually affects males in the fourth 
to fifth decade of life and may lead to cirrhosis, diabetes 
mellitus, panhypopituitarism, cardiomyopathy, arthritis and 
skin hyperpigmentation.1,2 In European and North-American 
Caucasians, HH has been linked to two missense mutations 
in the HFE gene, which maps to the 4 kb telomeric HLA-A 
locus on the short arm of chromosome 6.1-3 Furthermore, 
80% to 100% of Caucasian patients of Northern European 
descent with HH were shown to be homozygous for the 
C282Y mutation, whereas 4% to 6% were reported to 
be compound heterozygotes for the C282Y and H63D 
mutations.4
The frequencies of these HFE mutations are lower in 
Italian and Brazilian patients with HH,5-7 and approximately 
half of Brazilian patients with the classical disease 
phenotype are neither homozygous for C282Y nor compound 
heterozygous for the C282Y and H63D mutations.6 In 
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addition, none of these mutations were observed in African 
Americans with HH or in patients with African iron 
overload.8,9
Other mutations in the HFE gene, particularly S65C, 
have been implicated in HH and are generally found in a 
compound heterozygous state with either C282Y or H63D.3,10-
12
 Furthermore, mutations have been found in genes that have 
been recently implicated in iron homeostasis, including the 
transferrin receptor 2 (TfR2) gene on chromosome 7, the 
hepcidin antimicrobial peptide (HAMP) gene on chromosome 
19, the hemojuvelin (HJV) gene on chromosome 1 and 
the ferroportin 1 (Fpn1, also known as SCL40A1) gene on 
chromosome 2. The identification of causative mutations for 
HH in these genes has improved our understanding of iron 
homeostasis as well as suggested a genetic basis for a new 
classification of iron overload disorders.1,3,13 
HH has different phenotypic presentations. Types 1 and 3 
HH are characterized by the classical HH phenotype, which 
includes parenchymal iron overload and the presence of HFE 
and TfR2 mutations, respectively. Type 2 HH is associated 
with the previously described phenotype of juvenile 
hemochromatosis and mutations in the HAMP and HJV 
genes, whereas type 4 HH is associated with heterogeneous 
clinical and laboratory findings of iron overload that are 
more pronounced in the reticuloendothelial system.13
Mutations in the TfR2 gene, particularly the Y250X 
variant, and several different mutations in the SCL40A1 
gene have been reported in Caucasian, African and Asian 
patients with non-HFE linked iron overload.13-18 The 
prevalence of these recently described gene mutations in 
Brazilian patients with HH has not been assessed, and the 
purpose of the present study is to determine the frequency of 
non-classical HFE as well as TfR2 and SCL40A1 mutations 
in Brazilian subjects with the classical phenotype of HH.
PATIENTS AND METHODS
Subjects: Sixteen unrelated male patients from the 
metropolitan area of São Paulo, Brazil and three other 
subjects from Salvador, Bahia were studied. All had a 
diagnosis of HH based upon several criteria: 1) the absence 
of secondary causes of iron overload, including chronic 
hemolytic anemia, thalassemia major, sideroblastic and 
spur cell anemia, parenteral or dietary iron overload, alcohol 
abuse and chronic liver disease due to either hepatitis C or 
non-alcoholic steatohepatitis; 2) transferrin saturation greater 
than 50% and ferritin levels greater than 400 g/ L; and 3) 
grade III or IV siderosis by Perls stain and no other evidence 
of liver disease upon liver biopsy 2. Fifteen patients had been 
enrolled in a previous study and were already typed for the 
HLA-A C282Y and H63D mutations.6 All patients gave 
informed consent for participation in this study. 
The median age of the patients was 42 (range: 20-72) 
years. The clinical, laboratory and histological features of 
the patients are summarized in table 1.
DNA extraction: Genomic DNA was extracted from 
peripheral blood leukocytes using the DTAB/CTAB 
technique.19
Determination of HFE and non-HFE mutations: DNA 
samples from all patients, with the exception of those who 
were previously confirmed as homozygous for the C282Y 
mutation,6 were tested with a reverse transcriptase-based 
assay, the Haemochromatosis StripAssay A® (Vienna Lab, 
Labordiagnostika, GmbH, Vienna, Austria), according to the 
manufacturer’s instructions. This assay can detect twelve 
mutations in the HFE gene, which are V53M, V59M, H63D, 
H63H, S65C, Q127H, P160delC, E168Q, E168X, W169X, 
C282Y and Q283P, four mutations in the TfR2 gene, which 
are E60X, M172K, Y250X and AVAQ594-597del, and two 
mutations in the SCL40A1gene, which are N144H and 
V162del.
Statistical analysis: Clinical and laboratory data are 
shown in the text and tables as median and range. Differences 
in the frequencies of clinical and laboratory parameters 
were compared using the Fisher exact probability test when 
appropriate. A p value < 0.05 was considered to be significant.
RESULTS
The C282Y and H63D mutation status for each patient in 
our cohort is shown in Table 2. 
Table 1 - Clinical and laboratory features of Brazilian pa-
tients with HH
Clinical and laboratory features
Age at onset Median [range]
42 [20-72 ] years
Signs and Symptoms
 Chronic liver disease
 Diabetes 
 Impotence
 Skin hyperpigmentation
 Panhypopituitarism
 Cardiac Insufficiency
 Arthritis
Number (%)
14 (74)
4 (21)
3 (19)
1 (15)
1 (15)
1 (15)
1 (15)
Laboratory features
 Iron saturation (%)
 Ferritin (mg/mL)
 ALT IU/L (normal: ≤ 20)
 Bilirubin mg/dL (normal ≤ 1.1)
 Albumin g/dL (normal 3.5-5.0)
Median [range]
93 [55-100]
1102 [563-13.170]
57 [20-187]
1.5 [0.6-7.2]
4.3 [2.7-4.9]
Liver biopsy
 Grade III Siderosis
 Grade IV Siderosis
 Cirrhosis
Number (%)
8 (42)
11 (58)
14 (73)
839
CLINICS 2009;64(9):837-41 HFE and Non-HFE Mutations in Hemochromatosis
Bittencourt PL et al.
Table 2 - Clinical and laboratory features of Brazilian patients with hemochromatosis with and without homozygosity for 
C282Y mutation
C282Y (+/+)
(n=9)
C282Y (+/-) or (-/-)
(n=10)
Age at onset Median [range]
40 [36-47] years
Median [range]
44 [20-72] years
Signs and symptoms of 
chronic liver disease
Number (%)
8 (80)
Number (%)
6 (66)
Laboratory features
 Iron saturation (%)
 Ferritin (µg/mL)
 ALT IU/L (normal: ≤ 20)
Median [range]
96 [36-100]
1351 [576-13.170]
63 [36-187]
Median [range]
93 [58-100]
1057 [700-2333]
52 [20-98]
Liver biopsy
 Grade III Siderosis
 Grade IV Siderosis
 Cirrhosis
Number (%)
3 (33)
6 (66)
6 (66)
Number (%)
4 (40)
6 (60)
8 (80)
Numbers in parentheses are percentages
Nine (47%) patients were homozygous for the C282Y 
mutation. In addition, two (11%) patients were heterozygous 
for H63D, and one each (5%) was either heterozygous for 
C282Y or compound heterozygous for C282Y and H63D. 
None of the other ten HFE mutations and none of the 
TfR2 or SCL40A1 mutations that were included in the assay 
were found in these patients. 
A comparison of the clinical and laboratory profiles 
of patients with and without homozygosity for the C282Y 
mutation revealed that the former had higher ferritin levels 
and a lower age of onset for the disease when compared to 
their counterparts who were non-homozygous for C282Y. 
However, this difference was not significant (Table 2). 
DISCUSSION
Mutations in the HFE gene other than the C282Y 
substitution are uncommon in subjects with HH.1,3,10,13 In 
fact, the majority of patients who are not homozygous for 
the C282Y mutation are usually found to be compound 
heterozygotes for the C282Y and H63D mutations. Rare 
HFE mutations, such as S65C, E168X, W169X and Q238P, 
have been found in HH subjects who are heterozygous 
either for C282Y or H63D.1,3,10-12,20,21 The occurrence of the 
S65C mutation, as well as homozygosity for H63D,11,12,22,23 
has recently been associated with a milder form of iron 
overload disease. In the present study, no other mutation in 
the HFE gene, apart from C282Y and H63D, was identified 
in subjects with HH. Similar results were also reported by 
Cancado et al.,7 who were unable to find subjects with the 
S65C mutation in their cohort of Brazilian patients with iron 
overload. These findings are also in accordance with several 
other reports from Europe and North America,1,3 in which 
the S65C or another HFE mutation was found without the 
additional presence of either the C282Y and H63D mutations 
in only a few patients with HH or African iron overload. 
Non-HFE linked HH has been particularly associated 
with mutations in the ferroportin 1, transferrin receptor 2 and 
hepcidin genes.13 Hepcidin is a pleiotropic protein that plays 
a major role in cellular iron trafficking. Mutations in the 
HAMP gene have been associated with type 2 HH or juvenile 
iron overload, which is characterized by severe iron loading 
with end-stage organ damage in the second to third decade of 
life.1,3,13 Given that our patients do not share clinical features 
that are compatible with type 2 HH, HAMP gene variants 
were not assessed in the present study. 
On the other hand, our search for several common 
mutations in the TfR2 and SCL40A1 genes also yielded 
negative results. TfR2 variants have been implicated 
in HH type 3 HH, which exhibits a phenotype that is 
indistinguishable from classical disease phenotype of type 
1 HH.13 Unexpectedly, none of our patients with HH carried 
any one of the four most common TfR2 gene mutations, 
E60X, M172K, Y250X and AVAQ594-597del, that had been 
previously associated with non-HFE HH in Italy, Portugal 
and Japan.13-17 In addition, two mutations in the SCL40A1 
gene, which have been correlated with type 4 HH in Europe, 
North America and Australia,13 were not encountered in our 
cohort of Brazilian patients with HH. This is not surprising 
due to the stringent criteria we employed in this study, 
selecting only patients with parenchymal iron overload 
and grade III or IV hepatic siderosis. Type 4 HH is mainly 
associated with iron loading in reticuloendothelial cells, 
especially macrophages,13 and none of our patients had 
histopathological features that were consistent with type 4 
HH upon liver biopsy.
None of the individuals in our cohort of Brazilian 
patients with the classical phenotype of HH had any of the 
aforementioned non-C282Y mutations in the HFE gene or 
any mutations in the TfR2 and SCL40A1 genes. Less than 
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two-thirds of Brazilian subjects with either iron overload 
or HH were previously reported to be either homozygous 
for the C282Y mutation or compound heterozygous for the 
C282Y and H63D mutations.6,7,24 Moreover, the frequency 
of both of these HFE mutations was reported to be lower in 
Brazilians when compared to healthy subjects from Europe 
and North America.25,26
The absence of mutations in the TfR2 and SCL40A1 
genes in subjects with non-HFE HH has also been reported 
in other of European and North American patient cohorts, 
particularly in African-Americans and in patients with 
African iron overload.27-30 This observation suggests a 
possible role for other mutations in the known HH genes 
or even for other undiscovered genes that are also involved 
in iron homeostasis. In this regard, mutations in the iron 
responsive element of the ferritin heavy chain polypeptide 1 
gene (FTH1) have been recently reported in association with 
an autosomal dominant form of HH in Japan.17
Due to the ethnic background of the Brazilian 
population, other strategies, including direct sequencing 
or denaturing HPLC screening of candidate genes, may 
be more valuable in order to identify novel variants in the 
steadily increasing group of candidate genes for HH.
As previously shown in our first report,6 patients 
homozygous for the C282Y mutation tended to be younger 
and to have a more severe iron overload when compared to 
their counterparts who were non-homozygous for C282Y. 
Even after the inclusion of four additional subjects from 
the present cohort of HH patients, the difference is still 
not significant.  Interestingly, C282Y homozygotes have 
been shown to have more pronounced iron overload when 
compared to heterozygotes or to patients without the C282Y 
mutation in other populations.31
In summary, only 52% of Brazilian HH patients who 
were analyzed in this study were either homozygous for 
C282Y (n=9) or compound heterozygous for the C282Y and 
H63D mutations (n=1). None of these patients had another 
HFE variant or any mutation in the TfR2 and SCL40A1 
genes. 
ACKNOWLEDGMENTS
This study was in part supported by the São Paulo 
Research Foundation (FAPESB), grants number 0553/05 and 
01/09850-0 and Alves de Queiroz Family Fund for Research.
REFERENCES 
1.  Siah CW, Ombiga J, Adams LA, Trinder D, Olynyk JK. Normal iron 
metabolism and the pathophysiology of iron overload disorders. Clin 
Biochem Rev. 2006;27:5-16.
2.  Tavill AS. American Association for the Study of Liver Diseases; 
American College of Gastroenterology; American Gastroenterological 
Association. Diagnosis and management of hemochromatosis. 
Hepatology. 2001;33:1321-8.
3.  Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Pathogenesis 
of hereditary hemochromatosis. Clin Liver Dis. 2004;8:755-3, vii.
4.  Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular 
medicine and hemochromatosis: at the crossroads. Gastroenterology. 
1999;116:193-207.
5.  Camaschella C, Fargion S, Sampietro M, Roetto A, Bosio S, Garozzo 
G, et al. Inherited HFE unrelated hemochromatosis in Italian families. 
Hepatology 1999;29:1563-4.
6.  Bittencourt PL, Palácios SA, Couto CA, Cançado EL, Carrilho FJ, 
Laudanna AA, et al. Analysis of HLA-A antigens and C282Y and H63D 
mutations of the HFE gene in Brazilian patients with hemochromatosis. 
Braz J Med Biol Res. 2002;35:329-35.
7.  Cançado RD, Guglielmi AC, Vergueiro CS, Rolim EG, Figueiredo MS, 
Chiattone CS. Analysis of HFE gene mutations and HLA-A alleles in 
Brazilian patients with iron overload. Sao Paulo Med J. 2006;124:55-60.
8.  Monaghan KG, Rybicki BA, Shurafa M & Feldman GL. Mutation 
analysis of the HFE gene associated with hereditary hemochromatosis 
in African Americans. American Journal of Hematology. 1998;58:213-7.
9.  McNamara L, MacPhail AP, Gordeuk VR, Hasstedt SJ & Rouault T. Is 
there a link between African iron overload and the described mutations of 
the hereditary haemochromatosis gene? British Journal of Haematology. 
1998;102:1176-8.
10.  Pointon JJ, Wallace D, Merryweather-Clarke AT, Robson KJ. 
Uncommon mutations and polymorphisms in the hemochromatosis: 
genetics and beyond. Genet Test. 2000;4:151-61.
11.  Holmström P, Marmur J, Eggertsen G, Gåfvels M, Stål P. Mild 
iron overload in patients carrying the HFE S65C gene mutation: a 
retrospective study in patients with suspected iron overload and healthy 
controls. Gut. 2002;51:723-30.
12.  Mura C, Raguenes O, Ferec C. HFE mutation analysis in 711 
hemochromatosis probands: evidence for S65C implication in mild 
form of hemochromatosis. Blood. 1999;93:2502-5.
13.  Pietrangelo A.  Non-HFE hemochromatosis. Hepatology. 2004;39:21-9.
14.  Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, 
et al. The gene TfR2 is mutated in a new type of haemochromatosis 
mapping to 7q22. Nat Genet. 2000;25:14-15. 
15.  Mattman A, Huntsman D, Lockitch G, Langlois S, Buskard N, Ralston 
D, et al.  Transferrin receptor 2 TfR2 and HFE mutational analysis in 
non-C282Y iron overload: identification of a novel TfR2 mutation. 
Blood. 2002;100:1075-7.
16.  Roetto A, Totaro A, Piperno A, Piga A, Longo F, Garozzo G, et al. New 
mutations inactivating transferrin receptor 2 in hemochromatosis type 
3. Blood. 2001;97:2555-60. 
841
CLINICS 2009;64(9):837-41 HFE and Non-HFE Mutations in Hemochromatosis
Bittencourt PL et al.
17.  Hayashi H, Wakusawa S, Motonishi S, Miyamoto K, Okada H, Inagaki 
Y, et al. Genetic background of primary iron overload syndromes in 
Japan. Intern Med. 2006;45:1107-11. 
18.  Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, Castro 
O, et al. Iron overload in Africans and African-Americans and a 
common mutation in SCL40A1 ferroportin gene. Blood cells Mol Dis. 
2003;31:299-304.
19.  Gustincich S, Mamfioletti G, Delsal G, Schneider C & Carnici P. A fast 
method for high-quality genomic DNA extraction from whole blood. 
BioTechniques 1991;11:298-302.
20.  Salvioni A, Mariani R, Oberkanins C, Moritz A, Mauri V, Pelucchi 
S, et al. Prevalence of C282Y and E168X HFE mutations in an 
Italian population of Northern European ancestry. Haematologica. 
2003;88:250-53.
21.  Le Gac G, Dupradeau FY, Mura C, Jacolot S, Scotet V, Esnault G, et al. 
Phenotypic expression of the C282Y/Q283P compound heterozygosity 
in HFE and molecular modeling of the Q283P mutation effect. Blood 
Cells Mol Dis 2003;30:231-7. 
22.  Aguilar-Martinez P, Bismuth M, Picot MC, Thelcide C, Pageaux GP, 
Blanc F, et al.  Variable phenotypic presentation of iron overload in H63D 
homozygotes: are genetic modifiers the cause ? Gut. 2001;48:836-42. 
23.  de Diego C, Opazo S, Murga MJ, Martinez-Castro P.  H63D 
homozygotes with hyperferritinaemia: Is this genotype, the primary 
cause of iron overload? Eur J Haematol. 2007; 78:66-71. 
24.  Bittencourt PL. Assessment of HFE mutations in patients with iron 
overload. São Paulo Med J. 2007;125:65-7.
25.  Agostinho MF, Arruda VR, Basseres DS, Bordin S, Soares MC, Menezes 
RC, et al. Mutation analysis of the HFE gene in Brazilian populations. 
Blood Cells Mol Dis. 1999;25:3242-7.
26.  Pereira AC, Mota GF & Krieger JE. Hemochromatosis gene variants 
in three different ethnic populations: effects of admixture for screening 
programs. Human Biology. 2003,73:145-51.
27.  Barton EH, Barton JC, Hollowell WW, Acton RT.  Transferrin receptor-2 
TfR2 mutation Y250X in Alabama Caucasian and African American 
subjects with and without primary iron overload. Blood Cells Mol Dis. 
2001;27:279-84.
28.  Aguilar-Martinez P, Esculie-coste C, Bismuth M, Giansily-Blaizot 
M, Larrey D, Schved JF. Transferrin receptor-2 gene and non-C282Y 
homozygous patients with hemochromatosis. Blood Cells Mol Dis 
2001;27:290-5.
29.  McNamara L, Gordeuk VR, Macphail AP. Ferrportin Q284H mutations 
in African families with dietary iron overload. J Gastroenterol Hepatol 
2005;20:1855-8.
30.  Barton JC, Acton RT, Lee PL, West C. SLC40A1 Q248H allele 
frequencies and Q248H-associated risk of non-HFE iron overload 
in persons of sub-Saharan African descent. Blood Cells Mol Dis. 
2007;39:206-11.
31.  Barton JC, Shih WW, Sawada-Hirai R, Acton RT, Harmon L, Rivers 
C, et al. Genetic and clinical description of hemochromatosis probands 
and heterozygotes: evidence that multiple genes linked to the major 
histocompatibility complex are responsible for hemochromatosis. Blood 
Cells Mol and Dis. 1997;23:135-45;discussion 145a-b.

